Kodiak Sciences Inc. (NYSE:KOD) insider Jason Ehrlich sold 6,950 shares of the firm’s stock in a transaction on Friday, March 20th. The stock was sold at an average price of $45.00, for a total value of $312,750.00. Following the sale, the insider now directly owns 29,492 shares of the company’s stock, valued at $1,327,140. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Kodiak Sciences stock opened at $48.75 on Friday. The business has a fifty day simple moving average of $58.45 and a 200-day simple moving average of $44.59. Kodiak Sciences Inc. has a 12 month low of $5.86 and a 12 month high of $82.75.
Kodiak Sciences (NYSE:KOD) last issued its earnings results on Monday, March 16th. The company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.05).
Institutional investors have recently modified their holdings of the company. Meeder Asset Management Inc. acquired a new stake in shares of Kodiak Sciences in the fourth quarter worth $79,000. Great West Life Assurance Co. Can purchased a new stake in shares of Kodiak Sciences during the fourth quarter worth $91,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Kodiak Sciences during the fourth quarter worth $112,000. SG Americas Securities LLC purchased a new stake in shares of Kodiak Sciences during the fourth quarter worth $188,000. Finally, Principal Financial Group Inc. purchased a new stake in shares of Kodiak Sciences during the fourth quarter worth $222,000.
KOD has been the subject of several research reports. Morgan Stanley raised their price objective on Kodiak Sciences from $33.00 to $82.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. JPMorgan Chase & Co. initiated coverage on Kodiak Sciences in a research note on Tuesday, December 24th. They set an “overweight” rating and a $82.00 price objective for the company. Chardan Capital reissued a “buy” rating on shares of Kodiak Sciences in a research note on Thursday, January 23rd. SunTrust Banks assumed coverage on Kodiak Sciences in a research note on Wednesday, February 5th. They set a “buy” rating and a $101.00 price objective for the company. Finally, Jefferies Financial Group assumed coverage on Kodiak Sciences in a research report on Friday, January 3rd. They issued a “buy” rating and a $100.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $84.30.
About Kodiak Sciences
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.
Further Reading: How does a dividend reinvestment plan work?
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.